Shredding New Paths: Integrating Targeted Therapies in Ovarian and Endometrial Cancer – Clinical Runs and Future Slopes Industry Supported Symposium

This course offers an in-depth exploration of the latest advancements in targeted therapies for endometrial and ovarian cancers, with a particular focus on antibody-drug conjugates (ADCs) and personalized treatment strategies. Participants will learn about the evolving landscape of cancer therapies, including the pivotal role of PARP inhibitor (PARPi) monotherapy in first-line maintenance treatment, examining its long-term efficacy and implications for patient outcomes in ovarian cancer.

The curriculum will provide a comprehensive overview of emerging data from key clinical trials, including RUBY Parts I & II, GY018, AtTEnd, DUO-E, B21, Mirasol, Gloriosa, Piccolo and other significant studies. Through detailed analysis and discussions, attendees will interpret these findings to understand treatment outcomes, identify therapeutic trends, and integrate this knowledge into clinical practice.

By the end of the course, participants will be equipped with strategic insights to enhance their approach to managing endometrial and ovarian cancers, ensuring they are well-prepared to implement the latest evidence-based therapies in their clinical settings. Join us to deepen your understanding and improve patient care in these challenging malignancies.

The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: AbbVie and GSK

Target Audience

This course is designed for gynecologic oncologists, medical oncologists, and healthcare professionals involved in the management of gynecologic cancers. It is specifically developed for scholars, new investigators, fellows, residents, and any other medical professionals seeking to deepen their understanding of innovative therapies and emerging opportunities in the treatment of ovarian and endometrial cancers. The course is ideal for those eager to stay at the forefront of clinical practice, enhance their knowledge of cutting-edge treatments, and explore future directions in gynecologic oncology.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:

• Analyze Recent Advancements: Evaluate the latest developments in targeted therapies for endometrial and ovarian cancers, with a focus on emerging data from pivotal studies, such as RUBY Parts I & II, GY018, ATTEND, DUO-E, and B21, to inform clinical decision-making and therapeutic strategies in endometrial and antibody-drug conjugates (ADCs) and PARPi’s role specific to ovarian cancer.
• Assess the Role of PARP Inhibitors: Discuss the efficacy and clinical implications of new opportunities in ovarian and endometrial cancers, including long-term outcomes and patient selection criteria.
• Implement Personalized Treatment Strategies: Learn to develop personalized treatment plans that incorporate the latest evidence-based practices for managing endometrial and ovarian cancers, optimizing patient outcomes through tailored therapeutic approaches.

Moderators

Dr. Thomas Herzog

Faculty

Dr. Angeles Alvarez Secord

Dr. Jubilee Brown

Dr. Matthew Powell

Agenda

Shredding New Paths: Integrating Targeted Therapies in Ovarian and Endometrial Cancer – Clinical Runs and Future Slopes, an Industry Supported Symposium presented at the 2025 SGO Winter Meeting

This enduring education will be available on the GOG website for six months after the live presentation.

View Recording